アーカンソー州における脂肪肝の臨床試験
アーカンソー州内の拠点で、脂肪肝に関する8件の研究が参加者を募集しています。
アーカンソー州内の都市
公式研究テキスト（英語）
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Little Rock
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/30更新 · NCT07704892A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Little Rock
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/30更新 · NCT07701993A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Arkansas Gastroenterology - North Little Rock, North Little Rock
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Little Rock
- Akero Clinical Study Site, North Little Rock
被験者募集中第3相
18歳〜80歳 · 全性別 · 2026/09/21更新 · NCT06528314A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Arkansas Gastroenterology, P.A, Little Rock
- ARcare Center for Clinical Research, Little Rock
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/09更新 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Little Rock
- 89bio Clinical Study Site, North Little Rock
被験者募集中第3相
18歳〜80歳 · 全性別 · 2026/09/03更新 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Little Rock
- 89bio Clinical Study Site, North Little Rock
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/03更新 · NCT06419374A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Little Rock
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/07/27更新 · NCT07221227ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。